Last updated: 11/03/2018 23:00:08
A bioequivalence study of three, 2 mg nicotine chewing gums (two tests and one reference) in healthy adult smokers
GSK study ID
204979
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A Single-Dose, Open-Label, Three-way Crossover Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and one Reference) in Chinese Male Healthy Adult Smokers
Trial description: This is a randomized, open-label, single-dose, three-period, crossover, single-center comparative bioavailability (BA) study under fasting condition in Chinese healthy male adult participants with a history of cigarette smoking. The participants will be admitted to the investigational clinic at least 38 hours before dosing and will remain domiciled until the completion of all study procedures at approximately 24 hours after dosing. Three toothpastes (one is commercial non-medicated non-nicotine containing chewing gum and other two are nicotine containing gums) will be provided across the 3 treatment periods. During each of the 3 treatment periods, participants will be under supervision in a non-smoking area and will abstain from smoking.There will be a total of at least 7 days and not more than 10 days (clinical furlough period) between treatment periods. Twenty (20) blood samples will be collected for pharmacokinetic (PK) analysis at baseline and multiple time points following study drug administration. The trial duration will be approximately 49 days and up to 55 days from screening to study end including the screening period.
Primary purpose:
Other
Trial design:
Crossover Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Area under the curve from time zero to last sampling time [AUC(0-t)]
Timeframe: 2 days
Area under the curve from time zero extrapolated to infinity [AUC(0-inf)]
Timeframe: 2 days
Maximum plasma concentration (Cmax)
Timeframe: 2 days
Time to reach maximum plasma concentration (Tmax)
Timeframe: 2 days
Termination rate constant (Lambda_z)
Timeframe: 2 days
Elimination half life (t1/2)
Timeframe: 2 days
Systemic clearance (CL/F)
Timeframe: 2 days
Apparent volume of distribution (Vd/F)
Timeframe: 2 days
Secondary outcomes:
Not applicable
Interventions:
Other: Treatment A: Nicorette 2 mg coated mint gum
Other: Treatment B: Nicotinell 2 mg coated mint gum
Other: Treatment C: Nicotinell 2 mg coated fruit flavor gum
Enrollment:
45
Observational study model:
Not applicable
Primary completion date:
2016-12-06
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Tobacco Use Disorder
Product
nicotine polacrilex
Collaborators
Not applicable
Study date(s)
March 2016 to June 2016
Type
Interventional
Phase
1
Participation criteria
Sex
Male
Age
18 - 45 years
Accepts healthy volunteers
Yes
- Participants must understand and provide written informed consent before any assessment is performed, understand the study procedures, and be willing to complete the required assessments and the study.
- Chinese male participants between 18 and 45 years of age (inclusive) in general good physical health as judged by the Investigator.
- Use of other investigational drugs within 30 days or 10 half-lives of enrollment, whichever is longer.
Inclusion and exclusion criteria
Inclusion criteria:
- Participants must understand and provide written informed consent before any assessment is performed, understand the study procedures, and be willing to complete the required assessments and the study.
- Chinese male participants between 18 and 45 years of age (inclusive) in general good physical health as judged by the Investigator.
- Normal vital signs as follows:
- Oral body temperature between 35.0 and 37.5 ºC (95 and 99.5 F) inclusive
- Supine systolic blood pressure between 90 and 140 mmHg inclusive
- Supine diastolic blood pressure between 55 and 90 mmHg inclusive
- Pulse rate between 50 and 100 beats per minute (bpm) inclusive
- History of cigarette smoking of at least 10 cigarettes per day continuously for the past 3 months prior to screening.
- Body weight ≥ 50 kg, Body Mass Index (BMI) between 19 and 28 at screening.
- Ability to communicate and comply with all study requirements including the study specific chewing and swallowing procedures.
Exclusion criteria:
- Use of other investigational drugs within 30 days or 10 half-lives of enrollment, whichever is longer.
- History of or known hypersensitivity to the study drug or excipients.
- Diagnosis of long QT syndrome or QTc > 450 msec for males at screening.
- Any surgical or medical condition which may significantly alter the absorption, distribution, metabolism or excretion of any drug substance.
- History of malignancy or neoplastic disease of any organ system treated or untreated, orthostatic hypotension, cardiovascular disease, stroke, TIA, fainting or blackouts, clinically significant metabolic, pulmonary, neurological, hematological, autoimmune, psychiatric or endocrine disorders.. within the past 5 years prior to screening.
- Any evidence of cardiovascular, pulmonary, renal, hepatic, gastrointestinal, hematological, endocrinological, metabolic, autoimmune, neurological, psychiatric, other diseases or other clinically significant laboratory findings at screening.
- Participant has used any medication within two weeks before first scheduled study drug administration or within less than 10 times the elimination half-life of the respective drug.
- Unable to comply with the chewing and/or swallowing rhythm requirements (> 5% deviation of the total counts over 30 minutes) after trying either one of the two training sessions for 3 times.
- CO > 12 ppm after at least 38 hours confinement period in clinics prior to first dosing.
- Participants reports consumption of any drug metabolizing enzyme inducing or inhibiting aliments, evidence of current alcohol abuse or reports consumption exceeding 35 g of pure alcohol per day.
- Any history of drug hypersensitivity, asthma, urticaria, or other significant allergic diathesis, positive results in any of the virology tests for Human immunodeficiency virus (HIV)-Ab, Hepatitis C virus (HCV)-Ab, Surface antigen of the hepatitis B virus (HBs-Ag), and Tp-Ab.
- Participation in a previous clinical study with or without another investigational product and with ~470 ml blood drawn, or blood donation within the last 3 months prior to screening or previous enrollment into the current study.
- Vulnerable individual
- Inability to be venipuncture and/or tolerate venous access, unwilling to accept slight irritation of the throat and increased salivation due to nicotine gum administration.
- Unable or unwilling to discontinue the use or consumption of cigarette smoking, any nicotine containing products, Oral, local or topical pharmaceutical agents, consumption of caffeine/theophylline – containing products, grapefruit, Seville orange, orange, lemon, lime, apple, and pineapple, performance of unaccustomed strenuous physical exercise.
Trial location(s)
Study documents
No study documents available.
Results overview
Study Results yet to be posted
Recruitment status
Completed
Actual primary completion date
2016-12-06
Actual study completion date
2016-12-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website